Apnea of Prematurity
Conditions
Keywords
caffeine, apnea, prematurity
Brief summary
The aim of the present Phase III study is to evaluate the safety, efficacy and pharmacokinetics of Caffeine Citrate for treatment of apnea of prematurity in Japan.
Interventions
DRUGNPC-11 for intravenous or oral administration.
NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
Sponsors
Nobelpharma
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
28 Weeks to 33 Weeks
Healthy volunteers
No
Inclusion criteria
* Postconceptional age between 28 weeks and 33 weeks, and over 24 hours after birth. * At least 6 episodes of apnea (\>20 seconds in duration) in 24 hours. * Signed written informed consent from parent(s) or legal guardian(s).
Exclusion criteria
* Apnea due to: hypoxic-ischemic encephalopathy, meningitis, seizures, Grade III or IV intracranial hemorrhage, CNS depression from drugs administered to the mother during delivery, periventricular leukomalacia, pneumonia which does not improve even if it treats, hemoglobin\< 10 g/dL, sepsis, shock which does not improve even if it treats, blood pH\<7.2 on 2 consecutive determinations in spite of correction, serum calcium concentration \<7.0 mg/dL which does not improve even if it treats, serum glucose concentration \<4.0 mg/dL which does not improve even if it treats, congestive heart failure, symptomatic patent ductus arteriosus, rectal temperature\>38.5 °C on 2 consecutive readings, rectal temperature\< 35 °C on 2 consecutive readings, obstructive apnea. * Blood urea nitrogen \>20 mg/dL, serum creatinine \>1.5 mg/dL. * Serum AST or ALT \>3 times the upper limit of normal. * Requirement of mechanically-assisted ventilation ( containing nasal CPAP, nasal DPAP). * Previous treatment with methylxanthines within 7 days prior to study enrollment. * Previous treatment with H2 antagonists (i.e., cimetidine or ranitidine) within 7 days prior to study enrollment. * Receiving or experiencing the effects of CNS-active medication at the time of enrollment. * Participant of other clinical trial within 6 months. * Inappropriate to enter this clinical trial judged by the investigator in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rates for controlling of apnea episode in each observation day (at least 50% reduction of apnea episodes from baseline) | 1, 2, 3, 4, 5, 6,7, 8, 9 and 10 day |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change of frequency of apnea episode from baseline in each observation day | 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day | — |
| Time to event：Days until next events occurred | 1 to 10 day | Time to event：Days until next events occurred. The definition of events are, Not at least 50% reduction of apnea episode Not improving the frequency of episode from baseline Needs mechanical/bag valve mask ventilation. |
| The change of average duration time of apnea episode from baseline in each observation day | 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day | — |
| The change of lowest oxygen saturation during apnea episodes from baseline in each observation day | 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day | — |
| The proportion of less than 85% oxygen saturation during apnea episodes in each observation day | 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 day | — |
Countries
Japan
Outcome results
None listed